These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 22801068)

  • 1. Critical appraisal of trials for validation of 'risk-guided' cardiovascular disease prevention therapy.
    Castro A; Rosillo SO; Alonso A; Pedersen T
    Eur J Prev Cardiol; 2012 Aug; 19(2 Suppl):33-6. PubMed ID: 22801068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementation, target population, compliance and barriers to risk guided therapy.
    Tokgozoglu L; Bruckert E
    Eur J Prev Cardiol; 2012 Aug; 19(2 Suppl):37-41. PubMed ID: 22801069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk stratification in cardiovascular disease primary prevention - scoring systems, novel markers, and imaging techniques.
    Zannad F; De Backer G; Graham I; Lorenz M; Mancia G; Morrow DA; Reiner Z; Koenig W; Dallongeville J; Macfadyen RJ; Ruilope LM; Wilhelmsen L;
    Fundam Clin Pharmacol; 2012 Apr; 26(2):163-74. PubMed ID: 22220636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
    Fabbri G; Maggioni AP
    Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk-guided therapy: a first step to personalized medicine.
    Zannad F; Koenig W
    Eur J Prev Cardiol; 2012 Aug; 19(2 Suppl):5-6. PubMed ID: 22801063
    [No Abstract]   [Full Text] [Related]  

  • 6. [The PreFord Study. A prospective cohort study to evaluate the risk of a cardiovascular event (overall-collective) as well as a prospective, randomized, controlled, multicentre clinical intervention study (high-risk-collective) on primary prevention of cardiovascular diseases in the Ford Motor Company employees in Germany].
    Gysan DB; Latsch J; Bjarnason-Wehrens B; Albus C; Falkowski G; Herold G; Mey E; Heinzler R; Montiel G; Schneider CA; Stützer H; Türk S; Weisbrod M; Predel HG
    Z Kardiol; 2004 Feb; 93(2):131-6. PubMed ID: 14963679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical validation of genetic markers for improved risk estimation.
    Kessler T; Schunkert H
    Eur J Prev Cardiol; 2012 Aug; 19(2 Suppl):25-32. PubMed ID: 22801067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The science of risk models.
    Prieto-Merino D; Pocock SJ
    Eur J Prev Cardiol; 2012 Aug; 19(2 Suppl):7-13. PubMed ID: 22801064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aspirin for the primary prevention of adverse cardiovascular events.
    Estes K; Thomure J
    Crit Care Nurs Q; 2008; 31(4):324-39. PubMed ID: 18815480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Why do homocysteine-lowering B vitamin and antioxidant E vitamin supplementations appear to be ineffective in the prevention of cardiovascular diseases?
    Debreceni B; Debreceni L
    Cardiovasc Ther; 2012 Aug; 30(4):227-33. PubMed ID: 21884001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients' responsiveness to a decision support tool for primary prevention of cardiovascular diseases in primary care.
    van Steenkiste B; van der Weijden TM; Stoffers JH; GROL RP
    Patient Educ Couns; 2008 Jul; 72(1):63-70. PubMed ID: 18395393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conclusion.
    Koenig W; Zannad F
    Eur J Prev Cardiol; 2012 Aug; 19(2 Suppl):54-5. PubMed ID: 22801070
    [No Abstract]   [Full Text] [Related]  

  • 13. Do novel biomarkers add to existing scores of total cardiovascular risk?
    De Backer G; Graham I; Cooney MT
    Eur J Prev Cardiol; 2012 Aug; 19(2 Suppl):14-7. PubMed ID: 22801065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on aspirin in the treatment and prevention of cardiovascular disease.
    Hennekens CH
    Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reducing obesity and related chronic disease risk in children and youth: a synthesis of evidence with 'best practice' recommendations.
    Flynn MA; McNeil DA; Maloff B; Mutasingwa D; Wu M; Ford C; Tough SC
    Obes Rev; 2006 Feb; 7 Suppl 1():7-66. PubMed ID: 16371076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta-analysis of randomised controlled clinical trials.
    Hopper I; Billah B; Skiba M; Krum H
    Eur J Cardiovasc Prev Rehabil; 2011 Dec; 18(6):813-23. PubMed ID: 21878448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel approach to cardiovascular health by optimizing risk management (ANCHOR): a primary prevention initiative examining the impact of health risk factor assessment and management on cardiac wellness.
    Cox JL; Carr B; Vallis TM; Szpilfogel C; O'Neill BJ
    Can J Cardiol; 2011; 27(6):809-17. PubMed ID: 21944276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Controlled randomized clinical trials].
    Jaillon P
    Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The best of epidemiology and cardiovascular prevention in 2006].
    Thomas D; Collet JP; Cottin Y; Cournot M; Ducimetière P; Ferrières J; Paillard F; Valensi P; Zeller M; Cambou JP
    Arch Mal Coeur Vaiss; 2007 Jan; 100 Spec No 1():57-64. PubMed ID: 17405566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan.
    Morimoto T; Fukui T; Lee TH; Matsui K
    Am J Med; 2004 Oct; 117(7):459-68. PubMed ID: 15464702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.